From observations that certain sensory and environmental stimuli markedly affect the function of the endocrine glands under pituitary control, it was postulated (Marshall 1942 ) that the central nervous system exerts an influence over anterior pituitary activity.
Once this functional relationship had been established, attention was focused on the mechanism of this control. The possibility of direct nervous control by secretomotor nerves to the adenohypophyseal gland cells was ruled out by detailed histological studies (Rasmussen 1938 , Green 1951 , Wingstrand 1951 , and attention was turned to a previously described anatomical link between the hypothalamus and adenohypophysisthe hypophyseal portal vessels which were first described by Popa & Fielding (1930 , 1933 . There is now good evidence that these portal vessels form the functional link between the hypothalamus and anterior pituitary. The first direct evidence that these vessels were concerned with anterior pituitary function came with experiments dealing with pituitary stalk section. Normal pituitary function, e.g. cyclic gonadotrophin secretion, was prevented in rats whose stalk had been sectioned and a plate inserted. If no plate was inserted, the portal vessels regenerated and the animals showed normal cyclic reproductive activity (Harris 1950) . This was further confirmed by the demonstration that the pituitary gland transplanted to the subarachnoid space below the temporal lobe of hypophysectomized rats did not maintaiff normal activity while transplants to the subarachnoid space below the hypothalamus did support 'Fellow of the Foundations Fund for Research in Psychiatry.
Permanent address: Department of Physiology, Baylor University Medical School, Houston, Texas, U.S.A. pituitary activity (Harris & Jacobsohn 1952) . In the former case the pituitary transplant became revascularized by cortical and dural vessels, while in the latter the functional transplants became revascularized by portal vessels. Pituitary isolation experiments have been performed in many species with the same general results (see Harris 1955) . A recent experiment by a group in the United States clearly showed the functional relationship between the hypothalamus and anterior pituitary activity and the necessity for vascularization of the gland tissue by the portal vessels. These workers have shown that pituitary glands transplanted to the kidney capsule in hypophysectomized rats lose normal activity which is recovered when the grafts are subsequently retransplanted belowthehypothalamus (Nikitovitch-Winer & Everett 1958) .
Using classical neurophysiological techniques of lesion production and of stimulation, it has been demonstrated that destruction of various areas of the hypothalamus blocks the secretion of one or more of the pituitary trophic hormones, while stimulation of many of these same areas leads to increased pituitary secretion (see Harris 1960) . Based on these studies, attempts have been made to 'map' the hypothalamic areas involved with the various pituitary trophic hormones. This can be done only roughly since these areas are not merely nuclear aggregates but also contain nerve tracts leading to the hypothalamus at all angles. The picture is further complicated by the fact that these tracts probably carry impulses which are inhibitory as well as stimulatory. Much information has been accumulated from transplant and stalk section experiments and from lesion and stimulation experiments which indicates that the pituitary, when isolated from the hypothalamus, still maintains some degree of function. But the pituitary must be related to an intact hypothalamus for truly normal secretion of trophic hormones in the resting state and for enhancement or decrease in these secretions due to changing environmental or physiological conditions. The possibility that a stimulus might be humorally transmitted from the hypothalamus to the adenohypophysis was suggested in the 1930s (see detailed references, Harris 1955) and restated with more evidence in the 1940s. It has come to be known as the neurohumoral theory. According to this theory the central nervous system exerts a control over anterior pituitary activity not by direct nervous connexions, but by neurohumors which are generally liberated from hypothalamic neurons and reach the pituitary via the portal vessels.
[Recently a 'hindbrain factor' has also been suggested (Egdahl 1960 ) which can reach the pituitary via the systemic circulation and cause the release of adrenocorticotrophin (ACTH). This is still a humoral substance and if confirmed will not invalidate the neurohumoral theory.] Current knowledge of chemical transmission in the peripheral nervous system and neurosecretion by the hypothalamic-posterior pituitary complex strengthens the possibility that hypothalamic neurohumors exist which specifically evoke the release of pituitary trophic hormones. In the following discussion, these neurohumors will be referred to as releasing factors preceded by the hormone which they release, i.e. corticotrophin releasing factor (CRF), luteinizing releasing factor (LRF) and thyrotrophic releasing factor (TRF). Underlying the electrical changes, which are recognized as the nerve impulse or action potential, are complex chemical events. In addition, chemical substances are liberated at all nerve terminals, e.g. cholinergic or adrenergic substances from the autonomic system and oxytocin and vasopressin from hypothalamic neurosecretory cells. The cholinergic and adrenergic substances are liberated almost directly on to their effector cells while oxytocin and vasopressin are transported via a long vascular pathway (systemic circulation) to their effector cells in the mammary glands, uterus and kidney. Intermediate between these two extremes are the hypothalamic neurons which liberate at their terminals the postulated neurohumors (releasing factors) which travel via a short pathway (portal circulation) to their effector cells in the anterior pituitary. (Corticotrophin Releasing Factor, CRF) The final proof of the neurohumoral theory will be the isolation of the factor(s) which specifically stimulate trophic hormone release. Work along these lines began with the search for the substance which would release ACTH. Many substances have been thought to have this ability. Several of them, including a lipid or lipoprotein from bovine posterior hypothalamic tissue (Slusher & Roberts 1954 ) and histamine (Fuche & Kahlson 1957) , have never gained wide support and have been quickly rejected. Porter & Jones (1956) and Porter & Rumsfeld (1956) collected blood from the empty sella turcica of hypophysectomized dogs (thus presumably partly of pituitary portal vessel origin) and isolated from it (but not from systemic blood from the carotid artery) a protein substance which released ACTH in rats in which the normal release of ACTH following surgical stress had been blocked with hydrocortisone. This finding provided the most direct data regarding humoral control of ACTH via the portal vessels and caused considerable interest; however, no work has yet been published confirming these studies or further characterizing the suspected protein material.
Release of Corticotrophin
The suggestion that vasopressin might be the neurohumoral mediator (Martini & Morpurgo 1955 , Sobel et al. 1955 , McCann 1957 others) stimulated a great deal of research and prompted considerable controversy. Vasopressin (both commercial Pitressin and synthetic vasopressin) has the ability to release ACTH, as measured by adrenal ascorbic acid depletion, in animals whose normal response to stress-induced release of ACTH has been prevented by procedures such as lesions in the hypothalamus. Nembutal and morphine treatment, administration of hydrocortisone and transplantation of the pituitary to the eye (reviewed by Fortier & de Groot 1959) . The effect of vasopressin is only partly due to release of pituitary ACTH since vasopressin has a direct effect on the adrenal (Hilton 1960 ) and potentiates the action of ACTH on the adrenal, as has been shown by Royce & Sayers (1958) . Evidence such as the demonstration that the secretion of vasopressin and ACTH may be dissociated has suggested that vasopressin is not the physiological stimulus to ACTH production.
Two separate groups in the United States and Canada independently isolated a peptide from neurohypophyseal and from hypothalamic tissue which had the ability to release ACTH from pituitary tissue in vitro (Guillemin & Rosenberg 1955 , Saffran et al. 1955 , Guillemin et al. 1957 ). This unique peptide is distinct from vasopressin and appears to be a corticotrophin releasing factor (CRF). The work of these two groups was at first severely criticized because of the in vitro method which they used. But both groups independently performed experiments to satisfy the doubts raised by their critics and firmly established that their CRF material was actually releasing ACTH from the pituitary and was not acting merely by potentidting ACTH or by preventing its destruction (Guillemin & Schally 1959 , Saffran 1959 ). Guillemin's CRF preparation (fraction D) was shown (Clayton et al. 1957) to release ACTH in vivo in human subjects as evidenced by increase in plasma 17-hydroxycorticosteroids. Rats whose adrenal corticosteroid response to stress was shown to be blocked by Nembutal-morphine administration or by median eminence lesions were used by Guillemin et al. (1959) as test animals and further demonstrated that CRF (fraction D) was capable of releasing ACTH in vivo with resultant increase in plasma corticosteroid levels in these animals. The increased steroid response was linearwhen plottedagainst log dose CRF over the range 10-1,000 ,g. Inthese same experiments, vasopressin was inactive until more than 100 milliunits (pressor activity) were used. Although CRF possesses some inherent pressor activity, none of its ACTH-releasing potency can be accounted for by this.
Two well-known hypothalamic peptides, oxytocin and vasopressin, are very closely related, having six of eight amino-acid residues in common and a common sequence of these residues about a sulphide linkage. The overlapping actions of these octapeptides can be explained by their close structural resemblance. Recently J I Harris (1959) has shown that oc-melanocyte-stimulating hormone (a-MSH) is a tridecapeptide and that the amino-acid sequence of this peptide is exactly that of the first 13 amino acids of the ACTH molecule-thusexplainingthe inherent melanocytestimulating ability of ACTH. Schally et al. (1960) have now found that there are two CRFs. The first, which they call a-CRF, is a peptide containing all the amino acids of oa-MSH plus threonine, alanine and leucine. This peptide has weak CRF activity and Schally suggests that it may be a precursor of ACTH. On the other hand 3-CRF is extremely potent and is considered the true corticotrophin-releasing factor. ,-CRF is an analogue of vasopressin containing all the amino acids of lysine vasopressin plus serine, histamine, alanine and arginine (Schally et al. 1958 ). The close chemical resemblance between vasopressin and r-CRF probably accounts for the overlapping activities which are inherent in these molecules. CRF has 10 % of the antidiuretic activity of vasopressin and in turn vasopressin releases ACTH with about 10% of the activity of highly purified CRF. The three hypothalamic peptides, vasopressin, oxytocin and CRF have common, structural relationships and therefore understandably overlapping activities. However, each has its specific target: vasopressin acts mainly on the kidney, oxytocin on the uterus and mammary gland, and CRF on the adenohypophysis. Considerable and impressive evidence is available supporting the theory that CRF, a unique hypothalamic peptide, is the physiological neurohumor activating the pituitary to release ACTH. Although the proof is not yet complete, the data clearly favour the existence and identity of this material.
Release ofLuteinizing Hormone (Luteinizing-releasing Factor, LRF) As was the case with CRF, several substances including cholinergic substances, those adrenergic in nature, intermedin, oxytocin and vasopressin, have been proposed as the luteinizing releasing factor (LRF). None of these proposed substances has stood the test of time and experiment. Professor Harris's group in London has been using the following approach to the problem. Cannulb made of fine platinum tubing were implanted in rabbits with the tip in the pars distalis and the flanged top fixed to the skull and covered with a cap. One week later, substances were infused into the conscious, intact rabbit directly into the pars distalis at a rate of0-06 mi/h for two-hour periods. Ovulation was used to assess the effectiveness of the infused material, being a specific indicator of luteinizing hormone (LH) release. Crude acetic acid extracts of cattle, rabbit and monkey median eminence tissue caused ovulation in female rabbits when infused into the pituitary (Campbell et al. 1961 , The rabbit is an animal in which ovulation is normally produced by the reflex stimulation of coitus. More than twenty times the intrapituitary dose is needed to elicit ovulation when the extract is infused intravenously. Nikitovitch-Winer (1962) found that intrapituitary infusions of these same median eminence extracts caused ovulation in rats in which spontaneous ovulation had been blocked with Nembutal . Rats normally ovulate spontaneously every four to five days; if they are kept in light-controlled quarters, and their cestrous cycles followed by vaginal smears, ovulation can be blocked by anmsthesia at a known critical period on the day before it is due. Again, more than twenty times the intrapituitary dose was needed to produce ovulation when the extracts were infused intravenously. This was clearly a specific effect of the median eminence extracts, because it was shown in both species that similarly prepared extracts of cerebral cortex, corpus callosum, and caudate nucleus, as well as preparations of synthetic lysine vasopressin, synthetic oxytocin, synthetic vasotocin, CRF, substance P, adrenaline, histamine and serotonin, all failed to cause ovulation. These results strongly suggest that there is a specific neurohumor (LRF) in median eminence extracts which stimulates the release of LH and subsequent ovulation. Work is now directed toward the isolation and characterization of this neurohumor. Similar work has been proceeding in France (Guillemin, personal communication) Release ofThyrotrophin (Thyrotrophin-releasing Factor, TRF) A group of Japanese workers has prepared crude aqueous extracts from the anterior hypothalamus of the dog which they claim are able to release thyrotrophin (TSH) from the pituitary in normal rats, and in those with hypothalamic lesions (Shibusawa et al. 1956 . TSH increase is assessed by thyroid 1311 uptake after a single injection of the extract or -after daily injections over a three to five week period. Although this work is suggestive, there are some difficulties. The time relations of these thyroid responses are open to question, the extracts are undoubtedly contaminated with many hypothalamic substances including vasopressin, and no hypophysectomized control animals have been used-concurrently in these studies to rule out the possibility that the extracts are acting on the thyroid and not causing the pituitary release of TSH. Using column chromatography, this group has isolated a fraction 'T9' of TRF which is active in accelerating the release of 1311 from the thyroid (Shibusawa, Yamamoto, Nishi, Abe & Tomic 1959) . This TRF material is produced in the anterior hypothalamus of the dog and is found in the neurohypophysis, anterior hypothalamus, blood serum, urine and cerebrospinal fluid in diminishing order of concentration. The high concentration of TRF found in these three latter fluids is surprising as it suggests great stability of the substance, but this is not consistent with the rapid systemic inactivation of releasing factors that one would expect considering their short transport via portal vessels down the pituitary stalk. Dr Schreiber and his group in Prague have also isolated a non-protein fraction from aqueous extracts of hypothalamus and temporal lobe which is active in increasing pituitary acid phosphatase activity in vitro (Schreiber & Kmentova 1959) . Although these extracts will also increase acid phosphatase activity in the kidney and liver, the authors have presented considerable evidence that pituitary acid phosphatase activity parallels TSH secretion. More recently this group has reported that their TRF extract, when injected directly into the gland, was active in releasing TSH from the pituitary transplanted to the eye, as assessed by maintenance of thyroid weight (Schreiber 1961) . This extract is not effective in increasing thyroid activity when administered systematically to the rat nor is it active in releasing TSH from the pituitary when incubated with the gland in vitro. Judgment should be reserved on the physiological role of this TRF until it has been shown by methods more specific than acid phosphatase activity that it stimulates the release of TSH in vivo and in vitro. The fact that Schreiber's TRF is not active systemically makes it unlikely that it is identical with Shibusawa's TRF; however, the work by these two groups provides a lead for future investigations.
Lesions which effectively block TSH release almost invariably result in atrophy of the paraventricular nucleus which is associated with posterior pituitary hormone release (Greer & Erwin 1954, and others) . Electrical stimulation of the hypothalamus in the region of the supra-opticohypophyseal tract, known to be effective in releasing posterior pituitary hormones, results in increased thyroid activity (Harris & Woods 1958) . Other procedures known to release vasopressin, e.g. hypertonic saline and warming in the guinea-pig also stimulate thyroid activity (Feuer & Harris, unpublished observations). Although some investigators disagree (Rose et al. 1960 ), there are suggestions in the literature that vasopressin increases thyroid function (Ogawa et al. 1956 , Dubreuil & Martini 1956 , Bottari 1957 ) and may be acting on the release of TSH. In some preliminary studies, we found that acetic acid extracts of median eminence tissue increased thyroid function in the rabbit (Schindler, Harris & Garcia, unpublished observations). From reciprocal relations in the secretion of ACTH and TSH, the possibility exists that these trophic hormones are stimulated by hypothalamic neurohumors which come from a common precursor. Thus peptides of structure similar to ,-CRF would be implicatedparticularly vasopressin analogues. Knowing that our median eminence extracts were contaminated with vasopressin, we thought it advisable to study the action of this compound in order to gain some knowledge concerning the possible nature of the chemical mediator releasing TSH.
The first change of thyroid function detectable after TSH is the release of thyroid hormone. This can be followed by measuring 1311 and is the chosen method of assessing transient TSH stimulation of thyroid function in the conscious, intact rabbit. We have been using the following method. Rabbits were injected with 1311 and six days were allowed to elapse for all the inorganic 131I to be excreted, leaving only 1"1I-labelled thyroid hormone in the blood and thyroid gland. Substances to be tested were infused intravenously over a two-hour period. Blood samples were taken before the infusion (zero time sample) and at hourly intervals thereafter, and the radioactivity of these samples counted. Any infused material which increasedthyroidfunction would result in a release of 1311-labelled thyroid hormone from the gland which would be detected as an increase in radioactivity in the blood collected. It was found that the thyroid response to TSH (calculated as percentage of the thyroid hormone released from the 4' S Section ofEndocrinology 129 gland by a given stimulus) was linear over the range 10-1,000 milliunits TSH when plotted as the log of TSH dose. Having established a method of measuring transient stimulation of thyroid function in the conscious, intact rabbit, we proceeded to infuse vasopressin. Vasopressin (both purified and synthetic) infused at rates of 2 8 to 22 milliunits/minute for two hours led to an increased blood radioactivity and this was shown by chromatographic methods to be 13II-labelled thyroxine similar in every respect to that seen following TSH. This looked promising, and the next question to be answered was the site of action of vasopressin. Was it acting as a possible neurohumor causing the release of pituitary TSH which was in turn stimulating the thyroid, or was it acting directly on the thyroid gland? A large series of rabbits was divided into three groups: normal, hypophysectomized and sham operated. Vasopressin infusions resulted in comparable increased thyroid function (increased release of thyroxine) in all three groups including the hypophysectomized rabbits, thus establishing that vasopressin was not the hypothalamic neurohumor and was not acting via the release of TSH. This was further confirmed by experiments in collaboration with Dr El Kabir who used a sensitive in vitro method and found no change in plasma TSH levels before and after vasopressin infusions. It therefore appears that in the rabbit vasopressin acts directly on the thyroid gland.
Comments and Conclusions
Our experiments with vasopressin illustrate some of the difficulties in this field. One cannot proceed too far with crude extracts because of the possibility of contaminants which may mimic the action of the sought-after releasing factor or may in some way potentiate or even interfere with the action of this releasing factor or the trophic hormone released. This work requires the close collaboration of physiologists and biochemists. The methods used to assess release of pituitary trophic hormones must be specific. The releasing factors should be tested and shown active by several unrelated in vivo and in vitro methods. The close structural resemblance of hypothalamic peptides and hence their overlapping spheres of activity will have to be taken into account, and in most cases one would expect the true physiological releasing factor, when highly purified, to be active in doses smaller than any other natural substance.
Finally the most difficult aspect of the whole problem may well be the isolation of the releasing factors from pituitary portal blood and the demonstration that the portal blood concentration of these substances alters in response to changing physiological or experimental conditions and that the secretion of pituitary trophic hormones is correlated with this varying concentration.
In conclusion, the past fifteen years have led to great advances in basic knowledge of pituitary physiology. Although the feed-back mechanism of pituitary function is still recognized, it is less important than central nervous system regulation of the pituitary. The site of action of this feed-back mechanism may well be the hypothalamus as well as the pituitary. The main reflex regulation of pituitary trophic hormone secretion is the central nervous system with pathways feeding into the hypothalamus where hypothalamic neurons release neurohumors which are picked up by capillaries in the median eminence and carried via the pituitary portal vessels totheadenohypophysis where they exert their action, causing the release of pituitary trophic hormones ACTH, TSH and gonadotrophins. These neurohumors (releasing factors) fulfil the classical criteria for endocrine substances. They are present in an area whose destruction leads to an endocrine deficiency (e.g. failure of the hypothalamically lesioned animal to release ACTH in response to stress stimuli) and this deficiency can be corrected by administration of the substance (e.g. CRF causing ACTH release in the lesioned animal).
Dexamethasone Suppression Tests in Graves' Disease [Abridged] by I C Gilliland MD FRCPEd and M B Ghose MRCP (London)
A previous communication showed that the level of thyroid stimulating hormone (TSH) was raised in 15 out of 18 patients with Graves' disease (Gilliland & Strudwick 1956 ). TSH was not, however, the cause of the exophthalmos and some other factor was involved. Smelsner & Ozanics (1955) , after some careful studies of pituitary extracts with experimental animals, suggested that the additional factor was ACTH. For this reason we decided to investigate ACTH in Graves' disease. This work is still in progress.
Method
The patients studied were untreated and obvious cases of Graves' disease. Their ages ranged from 20 to 54; there were 8 women and 6 men. Not only was the diagnosis clinically obvious but hyperthyroidism was confirmed by radioactive iodine tests. The BMR varied from +40% to +90%. They had uniform thyroid involvement and had exophthalmos or ophthalmoplegia and frequently both. In 2 cases the eye signs were the presenting symptoms.
Dexamethasone was administered to suppress endogenous output of steroid metabolites; these were measured as 1 7-ketosteroids and 1 7-hydroxicorticosteroids by the method-of Moxham & Nabarro (1956) .
Dexamethasone was chosen as Jadresic et al. (1960) showed it to be the most efficient. Liddle (1960) showed that 2 mg per day for two days was sufficient to suppress hydroxicorticosteroid output to zero in normal people. The initial level employed was 3 mg a day for a week on the first 10 patients. This dose was doubled in the next 4 patients. Table 1 gives the excretion of 17-hydroxicorticosteroids before and after one week of 3 mg .00 dexamethasone per day. Table 2 shows the 17corticosteroid output after 6 mg a day.
Results

Discussion
In these patients with Graves' disease the endogenous output of corticosteroids was suppressed in only 1 of 10 patients at 3 mg a day and in 1 of 4 patients at 6 mg a day. This findingis in agreement with previous suggestions that there is an excess production of adrenal hormones in Graves' disease. Peterson et al. (1955) , using 14C-labelled steroids, showed that, although normal levels of circulating hormone were found, the clearance rates were much accelerated. This implied exces-
